Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Goodwin Biotechnology (GBI) and Spectros have partnered for the process development and cGMP manufacturing of an antibody.
Subscribe to our email newsletter
The antibody is a dye conjugate which will be used in Phase I and Phase II clinical trials.
Spectros CEO David Benaron said the collaboration with GBI on the conjugation of a fluorescent dye and a monoclonal antibody, the company intends to identify and minimize the residual tumor.
"We look forward to clinical trials with this agent, ProstaFluor, beginning next year," Benaron added.
Goodwin Biotechnology is a cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines, which specializes in cell line development, process development and GMP manufacturing of recombinant proteins.